A Centers for Disease Control and Prevention webpage that previously made the case that vaccines don't cause autism now says they might. WSJ: The contents of the webpage came up during Health Secretary Robert F. Kennedy Jr. Senate confirmation process. Sen. Bill Cassidy (R., La.) in February said Kennedy had assured him that, if he was confirmed, the CDC would "not remove statements on their website pointing out that vaccines do not cause autism." The revised webpage says: "The claim 'vaccines do not cause autism' is not an evidence-based claim because studies have not ruled out the possibility that infant vaccines cause autism. Studies supporting a link have been ignored by health authorities." The new text posted Wednesday also notes that the Department of Health and Human Services has launched "a comprehensive assessment" to probe the causes of autism.

Read more of this story at Slashdot.

A new treatment for tuberculosis could boost cure rates and shorten the time needed to treat the disease by months, trial results suggest. The Guardian: Globally, an estimated 10.7 million people fell ill with TB last year and 1.23 million died from it. In its annual report on tuberculosis, launched last week, the World Health Organization said it remained a "major global public-health problem" and the leading infectious cause of death. [...] Sorfequiline, a new antibiotic, showed stronger action against the deadly bacteria than existing treatments, with a comparable safety profile, researchers from the TB Alliance told the Union Conference on Lung Health in Copenhagen on Wednesday. The trial involved 309 people across 22 sites in South Africa, the Philippines, Georgia, Tanzania and Uganda, with different dose regimens. All participants had "drug-sensitive" tuberculosis, meaning a standard cocktail of drugs can safely treat them but researchers believe TB infections that are resistant to standard treatment could also be helped. The trial suggested a sorfequiline-based regimen could be used for anyone testing positive, said Dr Maria Beumont, vice-president of TB Alliance.

Read more of this story at Slashdot.

An anonymous reader shares a report: Federal health officials have linked two massive US measles outbreaks, confirming that the country is about two months away from losing its measles elimination status, according to a report by The New York Times. The Times obtained a recording of a call during which officials from the Centers for Disease Control and Prevention confirmed to state health departments that the ongoing measles outbreak at the border of Arizona and Utah is a continuation of the explosive outbreak in West Texas that began in mid- to late-January. That is, the two massive outbreaks are being caused by the same subtype of measles virus. This is a significant link that hasn't previously been reported despite persistent questions from journalists and concerns from health experts, particularly in light of Canada losing its elimination status last week. The loss of an elimination status means that measles will once again be considered endemic to the US, an embarrassing public health backslide for a vaccine-preventable disease.

Read more of this story at Slashdot.

An anonymous reader shared this report from the Guardian: The number of deaths linked to superbugs that do not respond to frontline antibiotics increased by 17% in England last year, according to official figures that raise concerns about the ongoing increase in antimicrobial resistance. The figures, released by the UK Health Security Agency, also revealed a large rise in private prescriptions for antibiotics, with 22% dispensed through the private sector in 2024. The increase in private prescribing is partly explained by the Pharmacy First scheme, a flagship policy of Rishi Sunak's government that allows patients to be prescribed antibiotics for common illnesses without seeing a GP, raising questions about whether the shift in prescribing patterns risks contributing to the rise in resistance. "Antibiotic resistance is one of the greatest health threats we face," said the UKHSA's chief executive, Prof Susan Hopkins. "More people than ever are acquiring infections that cannot be effectively treated by antibiotics. This puts them at greater risk of serious illness and even death, with our poorest communities hit the hardest... It's positive that we've seen antibiotic use fall in England within the NHS but we need to go further, faster," said Hopkins. "Please remember to only take antibiotics if you have been told to do so by a healthcare professional. Do not save some for later or share them with friends and family. If you have leftover antibiotics, please bring them to a pharmacy for appropriate disposal."

Read more of this story at Slashdot.

After more than a decade of planning, the launch of the African Medicines Agency (AMA) is being celebrated in Mombasa, Kenya, this week at the Seventh Biennial Scientific Conference on Medical Products Regulation in Africa. From a report: The agency's establishment marks a pivotal moment in Africa's public health, at a time when the need for biomedical research conducted in Africa, focused on African health problems, has never been greater. Africa holds higher levels of human genetic diversity than anywhere else on Earth, but this diversity has not been adequately studied. And many globally approved treatments and vaccines for diseases such as HIV/AIDS, malaria and tuberculosis are less effective, and can even be harmful in some people of African ancestry. This year, cuts of billions of US dollars in international funding for biomedical research and health services in Africa have left millions of people without access to life-saving treatments or, in the case of researchers and health-care workers, unemployed. This demonstrates the immense vulnerability that comes with relying on funding from external donors. What's more, Africa's phenomenal population growth and pace of urbanization is bringing fresh challenges -- as well as opportunities -- around health and disease. In Africa's cities today, the inhabitants of increasingly affluent neighbourhoods are demanding high-quality medicines and health care. But in low-income areas, high population density, inadequate housing and poor sanitation are facilitating the spread of respiratory and diarrhoeal infections. And everywhere, inadequate diets, air pollution, smoking and physical inactivity are driving increased rates of cardiovascular disease, diabetes and cancer. By 2100, Africa is expected to host 13 of the world's 20 largest cities, and such inequalities are likely to worsen.

Read more of this story at Slashdot.

The proliferation of difficult-to-treat bacterial diseases represents a growing threat, according to the World Health Organization's (WHO) Global Antibiotic Resistance Surveillance Report. Wired: The report reveals that, between 2018 and 2023, antibiotic resistance increased by more than 40 percent in monitored pathogen-drug combinations, with an average annual increase of 5-15 percent. According to data reported by more than 100 countries to WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), one in six laboratory-confirmed bacteria in 2023 proved resistant to antibiotic treatment, all related to various common diseases globally. For the first time, this edition of the report includes prevalence estimates of resistance to 22 antibiotics used to treat urinary tract, gastrointestinal, bloodstream, and gonorrheal conditions. The analysis focused on eight common pathogens: Acinetobacter spp, Escherichia coli, Klebsiella pneumoniae, Neisseria gonorrhoeae, non-typhoidal Salmonella spp, Shigella spp, Staphylococcus aureus, and Streptococcus pneumoniae. The results show that resistant gram-negative bacteria pose the greatest threat. Of particular note are Escherichia coli and Klebsiella pneumoniae, which are associated with bloodstream infections that can lead to sepsis, organ failure, and death. "More than 40 percent of E. coli and more than 55 percent of K. pneumoniae strains worldwide are now resistant to third-generation cephalosporins, the first-choice treatment for these types of infections," the report warns.

Read more of this story at Slashdot.

Food allergies in children dropped sharply in the years after new guidelines encouraged parents to introduce infants to peanuts, a study has found. The New York Times: For decades, as food allergy rates climbed, experts recommended that parents avoid exposing their infants to common allergens. But a landmark trial in 2015 found that feeding peanuts to babies could cut their chances of developing an allergy by over 80%. [non-paywalled source.] In 2017, the National Institute of Allergy and Infectious Diseases formally recommended the early-introduction approach and issued national guidelines. The new study, published Monday in the journal Pediatrics, found that food allergy rates in children under 3 fell after those guidelines were put into place -- dropping to 0.93% between 2017 and 2020, from 1.46% between 2012 and 2015. That's a 36% reduction in all food allergies, driven largely by a 43% drop in peanut allergies. The study also found that eggs overtook peanuts as the No. 1 food allergen in young children. The study did not examine what infants ate, so it does not show that the guidelines caused the decline. Still, the data is promising. While all food allergies can be dangerous, 80% of people never outgrow one.

Read more of this story at Slashdot.

Scientists from Spain and China have successfully repaired the blood-brain barrier in Alzheimer's-model mice, enabling the brain to naturally clear amyloid-beta plaques and reverse cognitive decline. "After just three drug injections, mice with certain genes that mimic Alzheimer's showed a reversal of several key pathological features," adds ScienceAlert. From the report: Within hours of the first injection, the animal brains showed a nearly 45 percent reduction in clumps of amyloid-beta plaques, a hallmark of Alzheimer's disease. The mice had previously shown signs of cognitive decline, but after all three doses, the animals performed on par with their healthy peers in spatial learning and memory tasks. The benefits lasted at least six months. These preclinical results don't guarantee success in humans, but they're an encouraging start, which the authors say "heralds a new era" in drug research. "The therapeutic implications are profound," claim the international team of researchers, co-led by scientists at the Institute for Bioengineering of Catalonia (IBEC) and the West China Hospital Sichuan University (WCHSU). The findings have been published in Signal Transduction and Targeted Therapy.

Read more of this story at Slashdot.

An anonymous reader quotes a report from the Conversation: Sound waves at frequencies above the threshold for human hearing are routinely used in medical care. Also known as ultrasound, these sound waves can help clinicians diagnose and monitor disease, and can also provide first glimpses of your newest family members. And now, patients with conditions ranging from cancer to neurodegenerative diseases like Alzheimer's may soon benefit from recent advances in this technology. I am a biomedical engineer who studies how focused ultrasound -- the concentration of sound energy into a specific volume -- can be fine-tuned to treat various conditions. Over the past few years, this technology has seen significant growth and use in the clinic. And researchers continue to discover new ways to use focused ultrasound to treat disease. [...] Research on focused ultrasound has primarily focused on the most devastating and prevalent diseases, such as cancer and Alzheimer's disease. However, I believe that further developments in, and increased use of, focused ultrasound in the clinic will eventually benefit patients with rare diseases. One rare disease of particular interest for my lab is cerebral cavernous malformation, or CCM. CCMs are lesions in the brain that occur when the cells that make up blood vessels undergo uncontrolled growth. While uncommon, when these lesions grow and hemorrhage, they can cause debilitating neurological symptoms. The most common treatment for CCM is surgical removal of the brain lesions; however, some CCMs are located in brain areas that are difficult to access, creating a risk of side effects. Radiation is another treatment option, but it, too, can lead to serious adverse effects. We found that using focused ultrasound to open the blood-brain barrier can improve drug delivery to CCMs. Additionally, we also observed that focused ultrasound treatment itself could stop CCMs from growing in mice, even without administering a drug. While we don't yet understand how focused ultrasound is stabilizing CCMs, abundant research on the safety of using this technique in patients treated for other conditions has allowed neurosurgeons to begin designing clinical trials testing the use of this technique on people with CCM. With further research and advancements, I am hopeful that focused ultrasound can become a viable treatment option for many devastating rare diseases.

Read more of this story at Slashdot.

Amazon Pharmacy will begin offering prescription pickup kiosks at its One Medical clinics starting in Los Angeles this December, allowing patients to collect common medications like antibiotics and inhalers without waiting for delivery. Reuters reports: The kiosks will be the first in-person pick-up service offered by Amazon Pharmacy, which has been providing prescription services primarily by delivery, said Hannah McClellan Richards, a vice president at Amazon Pharmacy. One Medical offers a membership structure that allows patients to access primary and urgent care at a subscription fee of $199 annually. Patients without a membership are still able to book an appointment and would be able to use the kiosk, the company said. Richards said in an interview that the company plans to expand the kiosk model outside of California in 2026 and is in talks with external health systems to introduce the machines through partnerships. Amazon does not plan to offer medicines that must be refrigerated, such as GLP-1 weight-loss drugs, or more tightly regulated prescriptions like controlled pain medicines through the kiosk. Inventory for each kiosk will be tailored to the provider, and patients would be able to consult a company pharmacist virtually, Amazon said in a press release.

Read more of this story at Slashdot.

XXongo writes: A New York times article suggests that merging the diagnosis of Asperger's syndrome into the Autism diagnosis in 2013, thus creating the "autism spectrum disorder," was not helpful (paywalled; alternative source). That broadening of the diagnosis, along with the increasing awareness of the disorder, is largely responsible for the steep rise in autism cases that Health Secretary Robert F. Kennedy Jr. has called "an epidemic" and has attributed to theories of causality that mainstream scientists reject, like vaccines and, more recently, Tylenol. But the same diagnosis now applies to both people who are non-verbal, frequently engage in self-destructive behavior such as pounding their heads against the floor, and may require full-time care, but also to people who are merely somewhat socially awkward, possibly engage in repetitive behaviors, and have a narrow range of interests. "Everything changed when we included Asperger's [in the diagnosis of autism]," said Dr. Eric Fombonne, a psychiatrist and researcher at Oregon Health & Science University. He noted that in the earliest studies of autism rates, 75% of people with the diagnosis had intellectual disabilities. Now, only about a third do.

Read more of this story at Slashdot.

Bruce66423 shares a report from The Guardian: Those diagnosed as small children typically have distinct genetic profile from those diagnosed later, [finds an international study based on genetic data from more than 45,000 autistic people in Europe and the U.S]. So, there's more than one condition out there that's being diagnosed as "autism." This, of course, messes with the debate about causes; one version of autism may be caused by something for which the evidence is very weak overall. "The term 'autism' likely describes multiple conditions," said Dr Varun Warrier, from Cambridge's department of psychiatry, senior author of the research. "For the first time, we have found that earlier and later diagnosed autism have different underlying biological and developmental profiles." "It is a gradient," added Warrier. "There are also many other factors that contribute to age of diagnosis, so the moment you go from averages to anything that is applicable to an individual, it's false equivalency." The analysis has been published in the journal Nature.

Read more of this story at Slashdot.

Cancer rates among people aged 15 to 49 have increased 10% since 2000 even as rates have fallen among older populations. Young women face an 83% higher cancer rate than men in the same age range. A 150,000-person study presented at the American Association for Cancer Research meeting found millennials appear to be aging biologically faster than previous generations based on blood biomarkers. That acceleration was associated with up to 42% increased risk for certain cancers including lung, gastrointestinal and uterine malignancies. Researchers are examining the "exposome" -- the full range of environmental exposures across a person's life. Studies have linked early-onset cancers to medications taken during pregnancy, ultra-processed foods that now account for more than half of daily calorie intake in the United States, circadian rhythm disruption from artificial light and shift work, and chemical exposures. Gary Patti at Washington University is using zebrafish exposed to known and suspected carcinogens to track tumor development. His lab has developed systems to scan blood samples for tens of thousands of chemicals simultaneously to identify signatures appearing more frequently in early-onset cancer patients.

Read more of this story at Slashdot.

"As awareness grows around the dangers of head trauma in sports, a small number of professional fighters and football players are turning to a psychedelic called ibogaine for treatment," reports the Los Angeles Times. They note that the drug's proponents "tout its ability to treat addiction, post-traumatic stress disorder and traumatic brain injury, or TBI. " Ibogaine, which is derived from a West African shrub, is a Schedule 1 drug in America with no legal medical uses, and experts urge caution because of the need for further studies. But the results, several athletes say, are "game-changing".... Although athletes are just discovering ibogaine, the drug is well known within the veteran community, which experiences high rates of brain injury and PTSD. In Stanford's study on the effects of ibogaine on special forces veterans, participants saw average reductions of 88% in PTSD symptoms, 87% in depression symptoms and 81% in anxiety symptoms. They also exhibited improvements in concentration, information processing and memory. "No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury," Dr. Nolan Williams, a professor of psychiatry and behavioral sciences, said in a statement on the results. "The results are dramatic, and we intend to study this compound further...." States can work faster than the federal government by carving out exemptions for supervised ibogaine therapy programs, similar to what Oregon has done with psilocybin therapy. Many states have also opted to legalize marijuana for medicinal or recreational use... In June, Texas approved a historic $50-million investment in state funding to support drug development trials for ibogaine, inspired by the results seen by veterans. Arizona legislators approved $5 million in state funding for a clinical study on ibogaine in March, and California legislators are pushing to fast-track the study of ibogaine and other psychedelics.

Read more of this story at Slashdot.